Vis enkel innførsel

dc.contributor.authorHjorth-Hansen, Henriken_US
dc.contributor.authorStenke, Leifen_US
dc.contributor.authorSöderlund, Stinaen_US
dc.contributor.authorDreimane, Artaen_US
dc.contributor.authorEhrencrona, Hansen_US
dc.contributor.authorGedde-Dahl, Thobiasen_US
dc.contributor.authorGjertsen, Bjørn Toreen_US
dc.contributor.authorHöglund, Martinen_US
dc.contributor.authorKoskenvesa, Perttuen_US
dc.contributor.authorLotfi, Kouroshen_US
dc.contributor.authorMajeed, Mohammed Waleeden_US
dc.contributor.authorMarkevärn, Beriten_US
dc.contributor.authorOhm, Lottaen_US
dc.contributor.authorOlsson-Strömberg, Ullaen_US
dc.contributor.authorRemes, Karien_US
dc.contributor.authorSuominen, Merjaen_US
dc.contributor.authorSimonsson, Bengten_US
dc.contributor.authorPorkka, Kimmoen_US
dc.contributor.authorMustjoki, Satuen_US
dc.contributor.authorRichter, Johanen_US
dc.PublishedEuropean Journal of Haematology 2015, 94(3):243-250eng
dc.description.abstractWe randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100 mg QD or imatinib 400 mg QD and report outcome as an intention-to-treat analysis with 36 months follow-up. Early cytogenetic and molecular responses were superior in the dasatinib group, with a tendency that imatinib patients caught up with time. For instance, MR3.0 was reached at 3 months in 36% vs. 8% (P = 0.02), at 12 months in 81% vs. 46% (P = 0.02) and at 18 months in 73% vs. 65% (n.s.) of the patients in the two groups. In contrast, MR4.5 was consistently superior in the dasatinib group at all time points from 6 months onwards, reaching 61% vs. 21% (P < 0.05) at 36 months. Sixty-four vs. 71% of the patients in the dasatinib and imatinib arms, respectively, remained on assigned drug. Dasatinib dose was frequently reduced, but with maintained excellent effect. One imatinib patient progressed to blastic phase, but no CML-related deaths occurred. In conclusion, our data compare favourably with those of the dasatinib registration study, DASISION. The fast and deep molecular responses induced by dasatinib compared with imatinib may be exploited to increase the proportion of patients who can achieve a treatment-free remission after treatment discontinuation.en_US
dc.rightsAttribution CC BY-NC-NDeng
dc.subjectRandomized controlled trialeng
dc.subjectdeep responseeng
dc.titleDasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006)en_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2014 the authors
dc.subject.nsiVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Hematologi: 775
dc.subject.nsiVDP::Midical sciences: 700::Clinical medical sciences: 750::Haematology: 775

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY-NC-ND
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY-NC-ND